RhG-CSF improves radiation-induced myelosuppression and survival in the canine exposed to fission neutron irradiation.

Fission-neutron radiation damage is hard to treat due to its critical injuries to hematopoietic and gastrointestinal systems, and so far few data are available on the therapeutic measures for neutron-radiation syndrome. This study was designed to test the effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in dogs which had received 2.3 Gy mixed fission-neutron-γ irradiation with a high ratio of neutrons (~90%). Following irradiation, rhG-CSF treatment induced 100% survival versus 60% in controls. Only two of five rhG-CSF-treated dogs experienced leukopenia (white blood cells [WBC] count < 1.0 × 10(9)/L) and neutropenia (neutrophil [ANC] count < 0.5 × 10(9)/L), whereas all irradiated controls displayed a profound period of leukopenia and neutropenia. Furthermore, administration of rhG-CSF significantly delayed the onset of leukopenia and reduced the duration of leucopenia as compared with controls. In addition, individual dogs in the rhG-CSF-treated group exhibited evident differences in rhG-CSF responsiveness after neutron-irradiation. Finally, histopathological evaluation of the surviving dogs revealed that the incidence and severity of bone marrow, thymus and spleen damage decreased in rhG-CSF-treated dogs as compared with surviving controls. Thus, these results demonstrated that rhG-CSF administration enhanced recovery of myelopoiesis and survival after neutron-irradiation.

Uso del factor estimulante de colonias granulocíticas en el tratamiento ambulatorio de la neutropenia postquimioterapia: aspectos de interés para el médico general integral / Using granulocyte colonies stimulant factor in the outpatient treatment of post chemotherapy neutropenia: interesting aspects for a general comprenhensive doctor

El factor estimulante de colonias granulocíticas (FEC-G)es un factor de crecimiento hematopoyético producidoen cantidades muy pequeñas in vivo, que regula la formación de los neutrófilos. El desarrollo de las técnicasde recombinación ha permitido la producción de cantidades suficientes de FEC-G para el tratamiento de la neutropenia iatrogénica......